Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.53 |
| ▸ | STS | P08842 | 4/20 | 0.50 |
| ▸ | PDE4A | P27815 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6344166 | 1.00 | THRA (0.55) | THRATHRBHSD17B3STSPDE4A | |
| SCHEMBL9558246 | 0.89 | HPGD (0.50) | THRATHRBPDE4APDE4BPDE4C | |
| SCHEMBL4083170 | 0.87 | ALDH1A1 (0.67) | THRAHSD17B3STSALDH1A1CYP1A2 | |
| SCHEMBL4020524 | 0.87 | ALDH1A1 (0.67) | THRAHSD17B3STSALDH1A1CYP1A2 | |
| SCHEMBL16672058 | 0.87 | ALDH1A1 (0.67) | THRAHSD17B3STSALDH1A1CYP1A2 | |
| SCHEMBL9557967 | 0.87 | HPGD (0.51) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL9588048 | 0.87 | THRA (0.66) | THRATHRBHSD17B3PDE4APDE4B | |
| SCHEMBL10574043 | 0.85 | ALDH1A1 (0.68) | THRAHSD17B3STSPDE4BALDH1A1 | |
| SCHEMBL9375696 | 0.85 | CTNNB1 (0.65) | THRATHRBHSD17B3PDE4APDE4B | |
| SCHEMBL6348421 | 0.84 | HPGD (0.51) | THRATHRBPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903114-B2 | Derivatives of naphthalene with COMT inhibiting activity | ORION CORPORATION (FI) | 2005-06-07 | — | — | US | disclosed |
| US-20040034011-A1 | Derivatives of naphthalene with comt inhibiting activity | ORION CORPORATION (FI) | 2004-02-19 | — | — | US | disclosed |
| EP-1317411-A1 | DERIVATIVES OF NAPHTHALENE WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002022551-A1 | DERIVATIVES OF NAPHTHALENE WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034011-A1 | Derivatives of naphthalene with comt inhibiting activity | COMT, CYP1A1, CYP1B1 | THRA 2912/4885THRB 2694/4885HSD17B3 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.